Anifrolumab Treatment Improves Quality of Life and Decreases Systemic Corticosteroid Use in Patients with Systemic Lupus Erythematosus
June 2024
Studysummary This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the effects of Anifrolumab on patients with systemic lupus erythematosus (SLE) through qualitative interviews and electronic medical records. Conducted with 14 patients for interviews and 16 for medical data, the study found significant improvements in symptoms such as fatigue, joint pain, and hair loss, as well as in daily life impacts like physical activity and social life. Disease activity and corticosteroid use decreased, while laboratory results improved. These findings highlight Anifrolumab's efficacy in alleviating both subjective symptoms and objective disease parameters in SLE patients.
